Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to ...

Around one hundred people a month in England have avoided a stroke over the last year thanks to a lifesaving NHS rollout of blood thinning medication. Over the last year, one million people with ...

They found this true for antihypertensives, lipid-lowering drugs, oral anticoagulants, and diuretics. However, they found that short-term use of 1 to 4 years of all cardiovascular medication ...

The continued quest for an 'ideal anticoagulant' led to the US FDA's recent approval of dabigatran etexilate, a prodrug for dabigatran (Pradaxa®, Boehringer Ingelheim), rivaroxaban, a Factor Xa ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, ...

The company is planning a “broad Phase 3 program” for two anticoagulants after they outperformed marketed medicines in a pair ...

Use of Anticoagulant Drug After Aortic Valve Replacement Lowers Mortality Risk Dec. 7, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Dan Bloomfield, MD, chief medical officer, Anthos, walks through promising findings demonstrating the efficacy of abelacimab, ...

These drugs included: Combining antihypertensives with lipid-lowering medications, diuretics, or oral anticoagulants for 5 years or more was also associated with a reduced risk. In contrast ...